Cellular Biomedicine Group Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
16.96 M |
Public Float |
12.45 M |
Cellular Biomedicine Group Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.24 |
Market Cap |
$274.98 M |
Shares Outstanding |
19.23 M |
Public Float |
11.1 M |
Address |
1345 Avenue of Americas New York New York 10105 United States |
Employees | - |
Website | http://www.cellbiomedgroup.com |
Updated | 07/08/2019 |
Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases The company was founded in 2009 and is headquartered in Cupertino, CA. . |